defactinib (Fakzynja)

Indications

• combination of avutometinib/defactinib indicated for the treatment of adult women with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy

Dosage

• AVMAPKI 3.2 mg administered orally twice weekly for the first 3 weeks of each 4-week cycle
• FAKZYNJA 200 mg administered orally twice daily for the first 3 weeks of each 4-week cycle

Mechanism of action

• avutometinib & defactinib are each kinase inhibitors

More general terms

• small inhibitory antineoplastic agent (ib drug)

Component of

• avutometinib/defactinib

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=25117126
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=25117347